{"id":"https://openalex.org/W2590741349","doi":"https://doi.org/10.1111/bjh.14501","title":"A phase 2 study of simtuzumab in patients with primary, post\u2010polycythaemia vera or post\u2010essential thrombocythaemia myelofibrosis","display_name":"A phase 2 study of simtuzumab in patients with primary, post\u2010polycythaemia vera or post\u2010essential thrombocythaemia myelofibrosis","publication_year":2017,"publication_date":"2017-02-21","ids":{"openalex":"https://openalex.org/W2590741349","doi":"https://doi.org/10.1111/bjh.14501","mag":"2590741349","pmid":"https://pubmed.ncbi.nlm.nih.gov/28220932"},"language":"en","primary_location":{"id":"doi:10.1111/bjh.14501","doi":"https://doi.org/10.1111/bjh.14501","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bjh.14501","pdf_url":null,"source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049400849","display_name":"Michael Robert Savona","orcid":"https://orcid.org/0000-0003-3763-5504","observed_orcids":["https://orcid.org/0000-0003-3763-5504"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael R. Savona","raw_affiliation_strings":["Vanderbilt University School of Medicine, Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University School of Medicine, Nashville, TN, USA","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben A. Mesa","raw_affiliation_strings":["Mayo Clinic, Scottsdale, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Scottsdale, AZ, USA","institution_ids":["https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112080484","display_name":"Hua Dong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hua Dong","raw_affiliation_strings":["Gilead Sciences, Inc., Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Inc., Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110198789","display_name":"Julia D. Maltzman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julia D. Maltzman","raw_affiliation_strings":["Gilead Sciences, Inc., Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Inc., Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101557480","display_name":"Shringi Sharma","orcid":"https://orcid.org/0000-0002-8162-5672","observed_orcids":["https://orcid.org/0000-0002-8162-5672"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shringi Sharma","raw_affiliation_strings":["Gilead Sciences, Inc., Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Inc., Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002922217","display_name":"Jeffrey Alan Silverman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey Silverman","raw_affiliation_strings":["Gilead Sciences, Inc., Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Inc., Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002632381","display_name":"Stephen T. Oh","orcid":"https://orcid.org/0000-0002-8564-5400","observed_orcids":["https://orcid.org/0000-0002-8564-5400","https://orcid.org/0000-0002-7330-0106"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen T. Oh","raw_affiliation_strings":["Washington University School of Medicine, St. Louis, MO, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University School of Medicine, St. Louis, MO, USA","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065621786","display_name":"Jason R. Gotlib","orcid":"https://orcid.org/0000-0001-8253-6156","observed_orcids":["https://orcid.org/0000-0001-8253-6156"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I4390039303","display_name":"Stanford Cancer Institute","ror":"https://ror.org/014qe3j22","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Gotlib","raw_affiliation_strings":["Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, USA","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5085521139"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":null,"fwci":3.1432,"has_fulltext":false,"cited_by_count":49,"citation_normalized_percentile":{"value":0.92319387,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"176","issue":"6","first_page":"939","last_page":"949"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.875},{"id":"https://openalex.org/keywords/primary-myelofibrosis","display_name":"primary myelofibrosis","score":0.8939999938011169},{"id":"https://openalex.org/keywords/loxl2","display_name":"LOXL2","score":0.9409999847412109},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.859000027179718},{"id":"https://openalex.org/keywords/bone-marrow-fibrosis","display_name":"bone marrow fibrosis","score":0.8370000123977661},{"id":"https://openalex.org/keywords/extracellular-matrix","display_name":"extracellular matrix","score":0.6259999871253967},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8460000157356262},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.6899999976158142},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.4620000123977661}],"concepts":[{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.9445639252662659},{"id":"https://openalex.org/C2778740236","wikidata":"https://www.wikidata.org/wiki/Q933716","display_name":"Polycythaemia","level":2,"score":0.922470211982727},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.9197461605072021},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8770390152931213},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6340745687484741},{"id":"https://openalex.org/C2779788118","wikidata":"https://www.wikidata.org/wiki/Q1542410","display_name":"Thrombocytosis","level":3,"score":0.5460566878318787},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5300858616828918},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5290310382843018},{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.5127018690109253},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4046691954135895},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.3610265552997589},{"id":"https://openalex.org/C89560881","wikidata":"https://www.wikidata.org/wiki/Q101026","display_name":"Platelet","level":2,"score":0.2290181815624237}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001706","descriptor_name":"Biopsy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001853","descriptor_name":"Bone Marrow","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011087","descriptor_name":"Polycythemia Vera","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D013920","descriptor_name":"Thrombocythemia, Essential","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D053614","descriptor_name":"Janus Kinase 2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D055728","descriptor_name":"Primary Myelofibrosis","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D055728","descriptor_name":"Primary Myelofibrosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D055728","descriptor_name":"Primary Myelofibrosis","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/bjh.14501","doi":"https://doi.org/10.1111/bjh.14501","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bjh.14501","pdf_url":null,"source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:28220932","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28220932","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of haematology","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G9000878657","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA016672","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320309542","display_name":"Karyopharm Therapeutics","ror":"https://ror.org/04ty78924"},{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1064291997","https://openalex.org/W1971649888","https://openalex.org/W1973054660","https://openalex.org/W1984626069","https://openalex.org/W1987085633","https://openalex.org/W2008799537","https://openalex.org/W2009766779","https://openalex.org/W2011833926","https://openalex.org/W2012124753","https://openalex.org/W2028961479","https://openalex.org/W2048247098","https://openalex.org/W2073653195","https://openalex.org/W2096042161","https://openalex.org/W2097059887","https://openalex.org/W2101037339","https://openalex.org/W2102579732","https://openalex.org/W2111463055","https://openalex.org/W2115351357","https://openalex.org/W2121743767","https://openalex.org/W2141249732","https://openalex.org/W2142506642","https://openalex.org/W2326795317","https://openalex.org/W2404783736","https://openalex.org/W2405712018","https://openalex.org/W2411784329","https://openalex.org/W2591000693"],"related_works":["https://openalex.org/W2593847736","https://openalex.org/W2591000693","https://openalex.org/W2979995858","https://openalex.org/W4405048848","https://openalex.org/W2778275419","https://openalex.org/W2591924358","https://openalex.org/W2891891723","https://openalex.org/W2114510117","https://openalex.org/W2310252693","https://openalex.org/W2285901068"],"abstract_inverted_index":{"Simtuzumab,":[0],"a":[1],"monoclonal":[2],"antibody":[3],"inhibitor":[4],"of":[5,26,166],"extracellular":[6],"matrix":[7],"enzyme":[8],"lysyl":[9],"oxidase-like-2,":[10],"showed":[11,83],"preclinical":[12],"promise":[13],"and":[14,39,103,120,154],"was":[15,28,131,176],"well":[16,177],"tolerated":[17,178],"in":[18,30,79,114,117,136,140,147,157,189],"clinical":[19,85,183],"studies.":[20],"A":[21],"phase":[22],"2,":[23],"open-label":[24],"study":[25],"simtuzumab":[27,49,61,93,142,149,159],"conducted":[29],"patients":[31,44,138,167,190],"with":[32,66,81,174,191],"primary":[33],"myelofibrosis":[34],"(MF),":[35],"post-polycythaemia":[36],"vera":[37],"MF":[38,192],"post-essential":[40],"thrombocythaemia":[41],"MF.":[42],"Fifty-four":[43],"were":[45,111],"randomized":[46],"to":[47,97],"receive":[48],"alone":[50,77,172],"(200":[51,62],"or":[52,60,63,78,173],"700":[53,64],"mg":[54],"[n":[55],"=":[56,69],"12":[57],"each":[58,71],"group])":[59],"mg)":[65],"ruxolitinib":[67,82,152,162,175],"(n":[68],"15":[70],"group)":[72],"for":[73],"24":[74,88,134,194],"weeks.":[75,89,195],"Simtuzumab":[76,171],"combination":[80],"no":[84],"benefit":[86,184],"at":[87,133],"The":[90],"mean":[91],"serum":[92],"trough":[94],"concentrations":[95],"appeared":[96],"increase":[98],"dose-proportionally":[99],"between":[100],"the":[101,141,148,158],"200-mg":[102,150],"700-mg":[104,143,160],"treatment":[105],"groups.":[106],"Therapy-related":[107],"serious":[108],"adverse":[109],"events":[110],"pyrexia,":[112],"pain":[113],"extremity":[115],"(both":[116],"1":[118,145],"patient)":[119],"infusion":[121],"reaction":[122],"(in":[123],"another":[124],"patient).":[125],"Bone":[126],"marrow":[127],"fibrosis":[128],"(BMF)":[129],"score":[130],"reduced":[132],"weeks":[135],"2":[137,155],"(16\u00b77%)":[139],"group,":[144,153],"(6\u00b77%)":[146],"+":[151,161],"(13\u00b73%)":[156],"group;":[163],"similar":[164],"numbers":[165],"had":[168],"increased":[169],"BMF.":[170],"but":[179],"did":[180],"not":[181],"produce":[182],"nor":[185],"consistently":[186],"reduce":[187],"BMF":[188],"by":[193]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-03-03T00:00:00"}